RxDoctor Payments Data

Megan Rettew, APRN

Family · Leesburg, VANPI 1720867781

Payments from drug & device makers

$3,625in general payments, 2019–2025

Across 147 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$553
  • Amgen$300
  • Pfizer$288
  • AstraZeneca$281
  • Lilly USA, LLC$221
  • plus $823 from 15 others

What the payments were for

  • Food & beverage$3,611100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,625 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$79,948
Medicare patients
355
Services billed
1,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide12$21,196
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,086
Rosuvastatin Calcium20$449
Atorvastatin Calcium61$364
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst32$354
Levothyroxine Sodium34$299
Losartan Potassium13$241
Amlodipine Besylate27$156
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$146
Azithromycin28$144
Doxycycline Hyclate14$133
Gabapentin18$126
Methylprednisolone15$108
Pantoprazole Sodium15$78
Metformin Hcl13$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$221$21,19612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.

Other family in Leesburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →